Compare · Health Care
AbbVie vs. Johnson & Johnson: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Johnson & Johnson's revenue of $94.2B was about 1.5 times AbbVie's $61.2B (Cityfort calculation: one divided by the other).
AbbVie's largest segment is Immunology, 49.7% of revenue in FY2025; Johnson & Johnson's largest segment is Innovative Medicine, 64.1% of revenue in FY2025.
United States brought in 76.2% of AbbVie's revenue in FY2025; United States brought in 57.1% of Johnson & Johnson's revenue in FY2025.
AbbVie's largest payer group is Customers in the US, 76.2% of revenue (FY2025); Johnson & Johnson's largest payer group is Customers in the US, 57.1% of revenue (FY2025).
Neither page lists the other among its competitors.
Each company in 5 points
AbbVie
1 · What it sells
AbbVie sells prescription medicines, and two immunology drugs, Skyrizi and Rinvoq, brought in $25.9 billion of its $61.2 billion FY2025 revenue.
Sources and detail on the AbbVie page2 · Who pays it
AbbVie reports no revenue by final payer and three US wholesalers handled substantially all its US drug sales; by location, the US paid 76.2% of FY2025 revenue and other countries 23.8%.
Sources and detail on the AbbVie page3 · What it keeps from $100
Of every $100 of FY2025 revenue, AbbVie kept $6.9 as net income after $8.2 of bought research and $9.2 of other expenses, mostly a non-cash contingent-consideration charge, while operating earnings were $24.6.
Sources and detail on the AbbVie page4 · Where the operating profit comes from
AbbVie reports one business segment and no profit by therapeutic area; immunology brought in $30.4 billion, or 49.7% of FY2025 revenue, and operating earnings were $15.1 billion.
Sources and detail on the AbbVie page5 · The one thing to watch
Skyrizi and Rinvoq were 48.7% of AbbVie's Q3 FY2026 revenue, and their basic US patents are expected to expire in 2033.
Sources and detail on the AbbVie page
Johnson & Johnson
1 · What it sells
Johnson & Johnson sells prescription medicines and medical devices, with FY2025 sales of $60.4 billion and $33.8 billion, or $94.2 billion in total.
Sources and detail on the Johnson & Johnson page2 · Who pays it
Johnson & Johnson reports no revenue by final payer and three wholesalers were 48.4 percent of gross revenues; by location, in FY2025 the US was 57.1% of sales, Europe 22.9%, Asia-Pacific and Africa 14.9% and the rest of the Western Hemisphere 5.2%.
Sources and detail on the Johnson & Johnson page3 · What it keeps from $100
Of every $100 that came in during FY2025, J&J kept $26.2 as net income, helped by a one-off talc reserve reversal of about $7.0 billion, while operating income, a Cityfort calculation from the FY2025 10-K, was $26.85 per $100 of sales.
Sources and detail on the Johnson & Johnson page4 · Where the operating profit comes from
Medicines made 84.4% of the two segments' FY2025 income before tax on 64.1% of sales, and devices made 15.6% on 35.9%; J&J reports no operating income by segment.
Sources and detail on the Johnson & Johnson page5 · The one thing to watch
About 76,500 US plaintiffs had pending talc lawsuits at Sep 27, 2026, and J&J's proposed $5.5 billion ovarian claims resolution needs at least 95% of remaining claims to take part.
Sources and detail on the Johnson & Johnson page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
AbbVie
Where $100 went · FY2025
| Research and development | $14.9 |
|---|---|
| Cost of products sold | $29.8 |
| Selling, general and admin | $22.9 |
| Other expenses (mostly contingent consideration) | $9.2 |
| Research bought from others (acquired IPR&D) | $8.2 |
| Interest | $4.3 |
| Income tax | $3.9 |
| Kept as net income | $6.9 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $61.2 billion × 100. Other expenses are other expense ($5.8 billion, which includes a $6.5 billion contingent-consideration charge offset by other items) plus a small currency loss, minus $241 million of other operating income. Tax includes $7 million for noncontrolling interests.
Johnson & Johnson
Where $100 went · FY2025
| Research and development | $14.3 |
|---|---|
| Cost of making products | $29.5 |
| Selling, marketing and admin | $23.1 |
| Restructuring and research write-downs | $0.3 |
| Interest expense | $0.9 |
| Income tax | $5.6 |
| Kept as net income | $26.2 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (sales of $94.2 billion plus $8.3 billion of interest and other income): each line = line ÷ $102.5 billion × 100. Interest and other income were $8.1 of each $100, and included the about $7.0 billion talc reserve reversal.
Line items differ because each company groups its costs its own way in its filings. Only on AbbVie's receipt: Cost of products sold; Selling, general and admin; Other expenses (mostly contingent consideration); Research bought from others (acquired IPR&D); Interest. Only on Johnson & Johnson's receipt: Cost of making products; Selling, marketing and admin; Restructuring and research write-downs; Interest expense.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
AbbVie
Johnson & Johnson
See the numbers
Net income
AbbVie
Johnson & Johnson
See the numbers
Free cash flow
AbbVie
Johnson & Johnson
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
AbbVie
- Revenue, per year
- +2.1%
- Net income, per year
- −22.2%
Johnson & Johnson
- Revenue, per year
- +4.6%
- Net income, per year
- +10.8%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
AbbVie
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $17.4B | $15.8B | +10.3% |
| Net income | $4.2B | $186M | +2,167.7% |
Johnson & Johnson
Q3 FY2026, the quarter to Sep 27, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $25.4B | $24.0B | +5.9% |
| Net income | $210M | $5.2B | −95.9% |
Sources: AbbVie S11, S25, S10, S1, S4, S9, S6, S8, S5, S7 · Johnson & Johnson S22, S9, S10, S20, S1, S18, S8, S16, S7, S14, S6
Who pays each company
AbbVie
- Customers in the US · 76.2% of revenue76.2% of FY2025 revenue ($46.6 billion). Three wholesalers handled substantially all US drug sales. Shares here are by location, because AbbVie does not report revenue by final payer.
- Customers outside the US · 23.8% of revenue23.8% of FY2025 revenue ($14.6 billion), sold mainly to wholesalers and through distributors.
Johnson & Johnson
- Customers in the US · 57.1% of revenue57.1% of FY2025 sales ($53.8 billion). Shares here are by location, because J&J does not report revenue by final payer.
- Customers in Europe · 22.9% of revenue22.9% of FY2025 sales ($21.5 billion).
- Customers in Asia-Pacific and Africa · 14.9% of revenue14.9% of FY2025 sales ($14.0 billion).
- Customers in the Western Hemisphere outside the US · 5.2% of revenue5.2% of FY2025 sales ($4.9 billion).
Revenue by segment
AbbVie
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Immunology | $30.4B | 49.7% |
| Neuroscience | $10.8B | 17.6% |
| Oncology | $6.7B | 10.9% |
| Aesthetics | $4.9B | 7.9% |
| Other key products | $3.7B | 6.1% |
| Eye care | $2.1B | 3.4% |
| All other | $2.6B | 4.3% |
Johnson & Johnson
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Innovative Medicine | $60.4B | 64.1% |
| MedTech | $33.8B | 35.9% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
AbbVie
FY2025
- United States76.2%
- Outside the US23.8%
Johnson & Johnson
FY2025
- United States57.1%
- Europe22.9%
- Asia-Pacific and Africa14.9%
- Western Hemisphere outside the US5.2%
Debt and cash
AbbVie
- Debt
- $80.9B
- Cash and investments
- $10.8B
On Sep 30, 2026.
At Sep 30, 2026 AbbVie's debt exceeded its cash by $70.1 billion, up from $62.3 billion at Dec 31, 2025. That is about 2.4 times EBITDA over the last four quarters (Cityfort calculation from the Q3 FY2026 10-Q and the Q4 FY2025 to Q3 FY2026 earnings releases).
Johnson & Johnson
- Debt
- $44.7B
- Cash and investments
- $17.2B
On Sep 27, 2026.
J&J states net debt of $27.4 billion at Sep 27, 2026 in its 10-Q. That is about 1.05 times operating cash flow over the last four quarters (Cityfort calculation from the FY2025 10-K, Q3 FY2025 10-Q and Q3 FY2026 10-Q).
Sources: AbbVie S4, S1, S2, S3, S20, S21, S7, S8, S9, S10 · Johnson & Johnson S6, S1, S3, S9
Who owns each company
AbbVie
- One class of shares.
- Officers and directors as a group: 0.1% of shares (as of Mar 6, 2026).
- BlackRock, Inc.: 8.1% (as of Jan 25, 2024).
- Vanguard Capital Management: 7.5% (as of Apr 29, 2026).
- The Vanguard Group: 0.0% (as of Mar 26, 2026).
Johnson & Johnson
- One class of shares.
- Officers and directors as a group: 0.2% of shares (as of Feb 24, 2026).
- BlackRock, Inc.: 7.7% (as of Jan 26, 2024).
- Vanguard Capital Management: 7.5% (as of May 1, 2026).
- State Street Corporation: 5.5% (as of Jan 30, 2024).
- 1 more holders on the Johnson & Johnson page.
Sources: AbbVie S15, S4, S16, S17, S26 · Johnson & Johnson S31, S6, S42
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
AbbVie
- Patents on the main drugs
Basic US patents on Skyrizi and Rinvoq are expected to expire in 2033. After 2025 settlements, AbbVie expects no generic Rinvoq tablets in the US before April 2037.
- Gross profit per $100
AbbVie kept $70.2 of gross profit per $100 of revenue in FY2025, against $69.0 in FY2021.
- Research spending
AbbVie spent $9.1 billion on research and development in FY2025, 14.9% of revenue, plus $5.0 billion on research bought from others.
- Range of products
Skyrizi and Rinvoq were 42.3% of FY2025 revenue and 48.7% in Q3 FY2026. Neuroscience brought in $10.8 billion, oncology $6.7 billion and aesthetics $4.9 billion in FY2025.
- Pricing power
Medicare price setting covers Imbruvica from 2026, Vraylar and Linzess from 2027 and Botox from 2028. Humira fell 49% in FY2025, which AbbVie ties mainly to biosimilar competition.
Johnson & Johnson
- Research spending
J&J spent $14.7 billion on research and development in FY2025, or 15.6% of sales. It also bought research assets, such as Firefly Bio for about $1.0 billion in 2026.
- Two businesses
Medicines were 64.1% and devices 35.9% of FY2025 sales. Immunology sales fell 11.8% in FY2025, and total sales still rose 6.0%.
- Global reach
Customers outside the US were 42.9% of FY2025 sales (Cityfort calculation from the FY2025 10-K), and J&J ran 63 manufacturing facilities, 22 of them in the US.
- Patents on the main medicines
A Tremfya patent family is projected to run to 2031 in the US. The Darzalex families expire in the US in 2029, and biosimilars of Stelara have launched.
- Pricing power
Price lowered FY2025 sales growth by 3.1%, while volume added 8.4%. Medicare negotiated prices for Xarelto, Stelara and Imbruvica started in 2026.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
AbbVie
- Skyrizi · Working: on track against what the company said$5.8B in Q3 FY2026, up from $4.7B
- Rinvoq · Working: on track against what the company said$2.7B in Q3 FY2026, up from $2.2B
- Neuroscience · Working: on track against what the company said$3.4B in Q3 FY2026, up from $2.8B
- Oncology · Mixed: partly on track$1.7B in Q3 FY2026, flat with a year earlier
- Aesthetics · Mixed: partly on track$1.18B in Q3 FY2026, down from $1.19B
- Apogee Therapeutics · New: recently announced$10.6B consideration, closed Sep 3, 2026
Johnson & Johnson
- Darzalex · Working: on track against what the company said$4.2B in Q3 FY2026, up 15.4%
- Tremfya · Working: on track against what the company said$2.4B in Q3 FY2026, up 68.3%
- Carvykti · Working: on track against what the company said$710M in Q3 FY2026, up 35.5%
- Neuroscience · Working: on track against what the company said$2.4B in Q3 FY2026, up 17.3%
- Cardiovascular devices · Mixed: partly on track$2.3B in Q3 FY2026, up 4.3%
- Ottava surgical robot · New: recently announcedFDA authorized in Q3 FY2026
- Firefly Bio and Sail Biomedicines · Early: too early to judgeAbout $1.0B and $0.8B paid in Q3 FY2026
Sources: AbbVie S7, S1, S18, S19, S4, S21 · Johnson & Johnson S6, S1, S13, S33
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
AbbVie
- Dividends per shareFY2023: $5.99 (216.7% of profit) · FY2024: $6.29 (257.7% of profit) · FY2025: $6.65 (275.8% of profit)
- Buybacks
- Dec 31, 2023: Bought 10 million of its own shares for $1.6 billion in 2023. ($1.6B)
- Dec 31, 2024: Bought 7 million shares for $1.3 billion in 2024. ($1.3B)
- Dec 31, 2025: Bought 3 million shares for $606 million in 2025. ($606M)
- Sep 30, 2026: Bought 5 million shares for $1.1 billion in the first nine months of 2026; about $1.8 billion of authorization remained at Sep 30, 2026. ($1.1B)
- AuditorErnst & Young LLP, since 2013
- Credit ratingMoody's and S&P, as stated in AbbVie's 10-Q: A2 (Moody's) and A- (S&P), outlook Stable (Moody's), positive (S&P) (Nov 3, 2026)
Johnson & Johnson
- Dividends per shareFY2021: $4.19 (62.0% of profit) · FY2022: $4.45 (71.4% of profit) · FY2023: $4.70 (88.3% of profit) · FY2024: $4.91 (84.1% of profit) · FY2025: $5.14 (46.2% of profit)
- Buybacks
- Dec 31, 2023: Repurchased $5.1 billion of shares in FY2023. ($5.1B)
- Dec 29, 2024: Repurchased $2.4 billion of shares in FY2024. ($2.4B)
- Dec 28, 2025: Repurchased $6.0 billion of shares in FY2025, through open-market purchases under a systematic plan to meet compensation programs. No publicly announced program was in place in Q4 FY2025. ($6.0B)
- Sep 27, 2026: Repurchased $6.0 billion of shares in the first nine months of FY2026. ($6.0B)
- AuditorPricewaterhouseCoopers LLP, since 1920
- Credit ratingNot checked for this page.
Sources: AbbVie S1, S4, S15 · Johnson & Johnson S3, S1, S6, S31
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: customer or supplier concentration, competition, pricing, debt, execution, legal cases. Every risk is on each company's page.
AbbVie
- Charges that rise with Skyrizi forecasts (other)AbbVie owes future payments mainly tied to Skyrizi sales, valued at $27.3 billion at Sep 30, 2026. Higher sales estimates raise this value, and the increase is a non-cash charge: $6.5 billion in FY2025.
Johnson & Johnson
- Tariffs and trade (other)J&J said on Jan 21, 2026 that it expected about $500 million of MedTech tariff costs in 2026. It recorded about $0.2 billion of tariff recoveries in Q3 FY2026.
Key facts
- How does AbbVie make money compared with Johnson & Johnson?
- AbbVie's revenue by segment in FY2025: Immunology 49.7%, Neuroscience 17.6%, Oncology 10.9%, Aesthetics 7.9%, Other key products 6.1%, and 2 more. Johnson & Johnson's revenue by segment in FY2025: Innovative Medicine 64.1%, MedTech 35.9%.
- Which is bigger by revenue, AbbVie or Johnson & Johnson?
- AbbVie reported $61.2B of revenue in FY2025, and Johnson & Johnson reported $94.2B in FY2025.
- How much net income did AbbVie and Johnson & Johnson report?
- AbbVie reported net income of $4.2B in FY2025, and Johnson & Johnson reported $26.8B in FY2025.
- How much of every $100 did AbbVie and Johnson & Johnson keep as net income?
- AbbVie kept $6.9 of every $100 that came in during FY2025, and Johnson & Johnson kept $26.2 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do AbbVie and Johnson & Johnson have?
- AbbVie had $80.9B of debt and $10.8B of cash and investments on Sep 30, 2026. Johnson & Johnson had $44.7B of debt and $17.2B of cash and investments on Sep 27, 2026.
- When do AbbVie's and Johnson & Johnson's fiscal years end?
- AbbVie: December 31. Johnson & Johnson: Sunday nearest the end of December.
Sources: AbbVie S2, S1, S10, S4, S3, S20, S21, S7, S8, S9 · Johnson & Johnson S3, S1, S6, S9
Built from each company's page. AbbVie updated Nov 6, 2026; Johnson & Johnson updated Nov 6, 2026.
Sources
AbbVie
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), AbbVie Inc. (SEC EDGAR), Feb 20, 2026
- S2Form 10-K for fiscal year 2023, AbbVie Inc. (SEC EDGAR), Feb 20, 2024
- S3Form 10-K for fiscal year 2022, AbbVie Inc. (SEC EDGAR), Feb 17, 2023
- S4Form 10-Q for Q3 2026 (quarter ended Sep 30, 2026), AbbVie Inc. (SEC EDGAR), Nov 3, 2026
- S5Form 10-Q for Q2 2026 (quarter ended Jun 30, 2026), AbbVie Inc. (SEC EDGAR), Aug 3, 2026
- S6Form 10-Q for Q1 2026 (quarter ended Mar 31, 2026), AbbVie Inc. (SEC EDGAR), May 8, 2026
- S7Q3 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Oct 30, 2026
- S8Q2 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Jul 31, 2026
- S9Q1 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Apr 29, 2026
- S10Q4 and full-year 2025 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Feb 4, 2026
- S11Q3 2025 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Oct 31, 2025
- S152026 proxy statement (DEF 14A) for the May 8, 2026 annual meeting, AbbVie Inc. (SEC EDGAR), Mar 23, 2026
- S16Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 26, 2026
- S17Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 29, 2026
- S18Form 8-K (Item 7.01) filed Jun 22, 2026: agreement to acquire Apogee Therapeutics, Exhibit 99.1, AbbVie Inc. (SEC EDGAR), Jun 22, 2026
- S19Form 8-K (Item 7.01) filed Sep 3, 2026: Apogee acquisition completed, Exhibit 99.1, AbbVie Inc. (SEC EDGAR), Sep 3, 2026
- S20Form 8-K (Item 8.01) filed Mar 4, 2026: $8.0 billion senior notes offering completed, AbbVie Inc. (SEC EDGAR), Mar 4, 2026
- S21Form 8-K (Item 8.01) filed Aug 18, 2026: $10.0 billion senior notes offering completed, AbbVie Inc. (SEC EDGAR), Aug 18, 2026
- S25SEC XBRL company facts for CIK 0001551152, SEC EDGAR, Nov 6, 2026
- S26SEC EDGAR submissions index for AbbVie Inc. (CIK 0001551152), SEC EDGAR, Nov 6, 2026
- S29Bambusa Therapeutics, Inc. final prospectus filed under Rule 424(b)(4), dated Oct 29, 2026 (competition section, pp. 146 and 197-198), SEC EDGAR (filed by Bambusa Therapeutics, Inc., CIK 0002044950), Oct 30, 2026
Johnson & Johnson
- S1Form 10-K, fiscal year 2025 (ended December 28, 2025), Johnson & Johnson (SEC EDGAR), Feb 11, 2026
- S3Form 10-K, fiscal year 2023 (ended December 31, 2023), Johnson & Johnson (SEC EDGAR), Feb 16, 2024
- S6Form 10-Q, Q3 FY2026 (quarter ended September 27, 2026), Johnson & Johnson (SEC EDGAR), Oct 21, 2026
- S7Form 10-Q, Q2 FY2026 (quarter ended June 28, 2026), Johnson & Johnson (SEC EDGAR), Jul 23, 2026
- S8Form 10-Q, Q1 FY2026 (quarter ended March 29, 2026), Johnson & Johnson (SEC EDGAR), Apr 22, 2026
- S9Form 10-Q, Q3 FY2025 (quarter ended September 28, 2025), Johnson & Johnson (SEC EDGAR), Oct 22, 2025
- S10Form 10-Q, Q2 FY2025 (quarter ended June 29, 2025), Johnson & Johnson (SEC EDGAR), Jul 24, 2025
- S13Earnings release, Q3 FY2026 (Form 8-K, Exhibit 99.1), Johnson & Johnson (SEC EDGAR), Oct 13, 2026
- S14Earnings financial schedules, Q3 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Oct 13, 2026
- S16Earnings financial schedules, Q2 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Jul 15, 2026
- S18Earnings financial schedules, Q1 FY2026 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Apr 14, 2026
- S20Earnings financial schedules, Q4 FY2025 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Jan 21, 2026
- S22Earnings financial schedules, Q3 FY2025 (Form 8-K, Exhibit 99.2), Johnson & Johnson (SEC EDGAR), Oct 14, 2025
- S31Proxy statement (DEF 14A), 2026 annual meeting, record date February 24, 2026, Johnson & Johnson (SEC EDGAR), Mar 11, 2026
- S33Form 8-K, Item 7.01: Firefly Bio acquisition, Sail Biomedicines collaboration, updated 2026 guidance, Johnson & Johnson (SEC EDGAR), Jul 29, 2026
- S42Schedule 13G, Vanguard Capital Management, 180,631,228 shares, event March 31, 2026, Vanguard Capital Management (SEC EDGAR), May 1, 2026
- S45Q4 2025 earnings call transcript, January 21, 2026 (LSEG StreetEvents, posted on J&J investor site), Johnson & Johnson (investor relations), Jan 21, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.